Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.

Naruto TairaKosuke KashiwabaraJunji TsurutaniMasahiro KitadaMasato TakahashiHiroaki KatoYuichiro KikawaEiko SakataYoichi NaitoYoshie HasegawaTsuyoshi SaitoTsutomu IwasaTsutomu TakashimaTomohiko AiharaHirofumi MukaiFumikata Hara

Published in: Breast cancer (Tokyo, Japan) (2021)

Keyphrases

phase ii study
metastatic breast cancer
placebo controlled
open label
locally advanced
advanced non small cell lung cancer
double blind
squamous cell carcinoma
rectal cancer
clinical trial
randomized controlled trial
radiation therapy
epidermal growth factor receptor